Cipla Share Price Live Updates: Cipla's Volatility Metrics
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
19 hours ago
- Time of India
Pharma stocks in focus as Trump warns tariffs could hit 250%
Pharma stocks such as Sun Pharma , Cipla , Dr Reddy's Laboratories , Lupin , and others will be in focus on Wednesday after US President Donald Trump said tariffs on imported pharmaceuticals could rise to as high as 250%. The proposed tariffs would start at a lower rate but escalate over time, he said in a CNBC interview. 'We'll be putting an initially small tariff on pharmaceuticals, but in one year, one-and-a-half years, maximum, it's going to go to 150% and then 250%, because we want pharmaceuticals made in our country,' Trump said. He did not specify the initial tariff rate. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Play War Thunder now for free War Thunder Play Now Undo Trump also indicated plans to impose tariffs on semiconductors and chips in the 'next week or so,' though no details were provided. Also Read: PNB Housing Finance, RBL Bank among 10 small-cap stocks where FIIs increased stake in Q1 The US administration has been pushing to bring pharmaceutical manufacturing back to domestic soil. Trump has threatened steep tariffs and demanded major drug suppliers cut costs or face further penalties. Live Events The United States is currently conducting a national security review of the pharmaceutical sector, with potential sector-specific tariffs under consideration. However, no timeline has been given for the release of the probe's findings. Currently, tariffs on pharmaceuticals and semiconductors between the US and the EU are set at zero under a framework agreement. However, if the US imposes new tariffs after its import investigation, these will be capped at 15% under the existing agreement. Also Read: These 10 stocks delivered consistent dividend yields over the last 3 years
Time of India
19 hours ago
- Time of India
Cipla Share Price Live Updates: Cipla's Price Action Indicates Bearish Trend
06 Aug 2025 | 09:22:04 AM IST Welcome to the Cipla Stock Liveblog, your ultimate source for real-time updates and analysis of one of the most prominent stocks in the market. Stay on top of the game with our comprehensive coverage, featuring the latest details on Cipla stock, including: Last traded price 1483.1, Market capitalization: 121153.04, Volume: 71429, Price-to-earnings ratio 22.47, Earnings per share 66.76. Get a holistic view of Cipla with our expert insights into both fundamental and technical indicators. Stay ahead of the curve as we bring you breaking news that can impact the stock's performance. Whether you're a seasoned investor or a curious market enthusiast, rely on us to provide you with valuable information and informed recommendations. Join us on this journey as Cipla thrives in the ever-changing market landscape. The data points are updated as on 09:22:04 AM IST, 06 Aug 2025 Show more
Economic Times
a day ago
- Economic Times
Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO
Mr. Krishnakumar Vaidyanathan, Executive Director & Chief Operating Officer Eris Lifesciences looks to leverage its experience in integrated diabetes portfolio to take a lead among the first wave of generic semaglutide anti-diabetic and weight-loss drugs to hit the market early next year, a top official said. The company is looking at a 'good' share of the market, Krishnakumar Vaidyanathan, executive director and chief operating officer of Eris Lifesciences, told ET in an interaction. Semaglutide is the active ingredient in Novo Nordisk's blockbuster drugs Wegovy and Ozempic. Its patent in India will expire in March 2026. 'We are gearing up to be among the first to enter the market post loss of exclusivity,' Vaidyanathan said. 'We expect the overall market for GLP-1 at the end of the first 12 months (after the loss of exclusivity) to be at least 10 million units… And we expect to get a good share of the market.' Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Eris Lifesciences' existing diabetes portfolio includes orals, insulin and GLP-1 in the form of liraglutide. Its network of field representatives, patient connect and service platform in this space gives the firm an advantage over others, Vaidyanathan said. 'We do this day in and day out because of insulin. That gives us the confidence that we'll be able to step this up for GLP-1 as well.'Globally, the GLP-1 market is dominated by Eli Lilly and Novo Nordisk, which are also the two biggest insulin companies in the world. 'Being successful and big in the insulin market provides a huge tailwind when it comes to selling GLPs,' Vaidyanathan said. 'We have combined service with technology and product to create a winning combination in insulin and GLP therapy entry is not any different, which also requires a lot of patient education over and above the service on using the pens,' he said. 'We have an integrated diabetes portfolio because we currently sell GLP-1 in the form of liraglutide.' Dr Reddy's Labs, Sun Pharmaceutical Industries, Cipla, Mankind Pharma, Torrent Pharmaceuticals, and Zydus Lifesciences are also among Indian drugmakers readying to launch generic semaglutide next year. Eris Lifesciences launched liraglutide, a once-a-week GLP-1 product, last September. 'We have taken very good market shares in all the other LOE (loss of exclusivity) opportunities that we have seen in diabetes,' Vaidyanathan said. 'We have taken market ranks of 1 to 5 in each one without exception – vildagliptin, sitagliptin, linagliptin, dapagliflozin and empagliflozin. That gives us the confidence that we should be getting a fair share of the market.' Vishal Manchanda, pharma analyst at brokerage Systematix Group, said its full portfolio of anti-diabetes drugs to offer to diabetologist, spanning all oral and injectable options, should give Eris Lifesciences 'a strong positioning in a market where the large pharma majors like Sun, Lupin, Dr Reddy's, Cipla, Mankind and Zydus come in with their dominant brand presence.'
